Drug agency FDC Ltd on Tuesday mentioned it has launched two variants of the COVID-19 drug Favipiravir beneath the model names PiFLU and Favenza. The Drug Controller Basic of India (DCGI) had earlier accepted using Favipiravir, an off-patent, oral antiviral drug that has been proven to quicken medical restoration in COVID-19 sufferers with delicate to reasonable signs, FDC mentioned in an announcement.
“Early prognosis and therapy will assist in arresting the deteriorating situation of sufferers, and we shall be working with the federal government and healthcare fraternity to make Favenza and PiFLU obtainable throughout the nation” FDC spokesperson Mayank Tikkha mentioned.
Each the merchandise are at the moment obtainable throughout the nation, the corporate mentioned.
The worth per pill is Rs 55 for each the variants, it added.
Shares of FDC Ltd closed at Rs 317.50 per scrip on BSE, down 1.17 per cent over earlier shut.